I
SNDX icon

InceptionR’s Syndax Pharmaceuticals SNDX Stock Holding History

InceptionR’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$496K Buy
+22,691
New +$472K 0.12% 315
2026
Q1 		– Sell
-10,747
Closed -$226K – 883
2025
Q4 		$226K Buy
+10,747
New +$187K 0.06% 512

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

InceptionR's SNDX Position: Q2 2026 in Review

InceptionR opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 22,691 shares worth $496K. The stake represents 0.12% of the portfolio and ranks #315 among its holdings. This is a return to the name: InceptionR previously reported a position in SNDX as recently as Q4 2025.

InceptionR first reported a position in SNDX in Q4 2025 and has held it in 2 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • InceptionR held 22,691 shares of Syndax Pharmaceuticals worth $496K as of Q2 2026.
  • Syndax Pharmaceuticals was a new InceptionR position in Q2 2026.
  • Syndax Pharmaceuticals made up 0.12% of InceptionR's portfolio in Q2 2026, its #315 holding.
  • InceptionR first reported a position in Syndax Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on InceptionR's 13F filing for Q2 2026, filed 11 Aug 2026.